List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Overview
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Companies Involved in Therapeutics Development
Abeona Therapeutics Inc
Amicus Therapeutics Inc
ArmaGen Inc
Denali Therapeutics Inc
Esteve Pharmaceuticals SA
JCR Pharmaceuticals Co Ltd
Lysogene SAS
Tega Therapeutics Inc
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Drug Profiles
AGT-184 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EGT-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Replace Sulphamidase for Mucopolysaccharidosis III (Sanfilippo Syndrome) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate SGSH for Mucopolysaccharidosis Type IIIA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JR-441 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LYSSAF-302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rebisufligene etisparvovec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Enzyme to Replace Sulphamidase for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Dormant Products
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Discontinued Products
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Product Development Milestones
Featured News & Press Releases
Feb 15, 2021: Lysogene reports LYS-SAF302 biomarker data presented at the WORLDSymposium 2021
Feb 12, 2021: New positive interim data on ABO-102 presented at WORLDSymposium
Feb 02, 2021: Abeona Therapeutics announces clinical investigator webinar to review ABO-102 Clinical Data presented at the 17th Annual WORLDSymposium
Dec 28, 2020: Lysogene reports positive biomarker data with LYS-SAF302
Dec 21, 2020: Abeona Therapeutics announces acceptance of late-breaker abstracts highlighting new clinical data for novel AAV-based gene therapies including rebisufligene etisparvovec at WORLDSymposium
Oct 15, 2020: Lysogene provides update on the AAVance clinical trial evaluating LYS-SAF302 in patients with MPS IIIA
Jun 05, 2020: Lysogene announces important updates on AAVance phase 2/3 clinical trial with LYS-SAF302 in MPS IIIA
Feb 25, 2020: Lysogene receives FDA fast track designation for LYS-SAF302 gene therapy in MPS IIIA
Feb 12, 2020: Abeona Therapeutics announces presentation on its MPS IIIA drug candidate ABO-102 at WORLDSymposium
Dec 20, 2019: Abeona Therapeutics receives European Medicines Agency PRIME Designation for ABO-102 Gene Therapy in MPS IIIA
Dec 18, 2019: Lysogene announces the publication of an article in the scientific journal "molecular therapy methods & clinical development” demonstrating the potential of its drug candidate LYS-SAF302
Oct 21, 2019: Abeona Therapeutics announces presentations at the 27th European Society of Gene and Cell Therapy (ESGCT) Congress
Jul 25, 2019: Abeona Therapeutics announces positive interim data from the ABO-102 phase 1/2 gene therapy clinical trial in MPS IIIA
Jul 25, 2019: Abeona Therapeutics announces positive interim data from the ABO-102 phase 1/2 gene therapy clinical trial in MPS IIIA
Jun 11, 2019: Lysogene announces first European patient treated in AAVance, Phase 2/3 clinical trial investigating LYS-SAF302, a gene therapy for the treatment of MPS IIIA (Sanfilippo Syndrome Type A)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Abeona Therapeutics Inc, 2021
Pipeline by Amicus Therapeutics Inc, 2021
Pipeline by ArmaGen Inc, 2021
Pipeline by Denali Therapeutics Inc, 2021
Pipeline by Esteve Pharmaceuticals SA, 2021
Pipeline by JCR Pharmaceuticals Co Ltd, 2021
Pipeline by Lysogene SAS, 2021
Pipeline by Tega Therapeutics Inc, 2021
Dormant Projects, 2021
Discontinued Products, 2021

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

Companies Mentioned
• Abeona Therapeutics Inc
• Amicus Therapeutics Inc
• ArmaGen Inc
• Denali Therapeutics Inc
• Esteve Pharmaceuticals SA
• JCR Pharmaceuticals Co Ltd
• Lysogene SAS
• Tega Therapeutics Inc